News
March 8, 2024
UPDATE: Investigational New Drug, ATA3219, Receives FDA Approval for Lupus Nephritis Treatment Study
The new drug application for the investigational therapy, ATA3219, for treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis) was approved for study by the U.S. Food and Drug Administration. The first trial participants are expected to be enrolled in the second half of 2024. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.
Get Lupus Research Headlines Emailed to You
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.
The latest from Inside Lupus Research
News
New Study Evaluates the Modified NIH Scoring System's Effectiveness in Predicting End-Stage Kidney Disease in Latin American People with Lupus Nephritis
News
New Study Highlights the Impact of Flares and Persistently Active Disease on Organ Damage in People with Systemic Lupus Erythematosus
News
FDA Accepts Supplemental Biologics License Application for Gayzva for Treatment of Lupus Nephritis
News
New Study Investigates the Role of microRNA-203 as a Potential Biomarker for Lupus Nephritis